Egle Therapeutics

Egle Therapeutics is a biotech startup that specializes in developing innovative immunotherapies. The company's primary focus is on targeting suppressor regulatory T cells (Tregs), which play a crucial role in the immune system. These cells are particularly relevant in the treatment of cancer and autoimmune diseases, where the immune response is often compromised.

Founded in 2020, Egle Therapeutics was established by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, Director of the Translational Immunotherapy Team at Institut Curie. The company's approach combines the use of antibody-specific targeting with modified cytokine, a type of small protein important in cell signaling, to either enhance or suppress the most immunosuppressive Tregs. This unique method aims to restore the immune response, offering potential breakthroughs in the treatment of severe diseases.

Egle Therapeutics operates in the biotech market, serving clients in the medical and healthcare sectors. The company's business model is centered around the development and commercialization of its first-in-class immunotherapies. The company generates revenue through the development of its drug pipeline, which includes novel immunotherapies against Tregs.

The company's name, Egle, is inspired by the Greek myth of Aglaea, symbolizing beauty, splendor, glory, and magnificence. This reflects the company's mission to bring hope to patients suffering from severe diseases and to deploy remarkable science to meet unmet medical needs.

Keywords: Egle Therapeutics, Biotech Startup, Immunotherapies, Suppressor Regulatory T cells (Tregs), Oncology, Autoimmune Diseases, Antibody-Specific Targeting, Modified Cytokine, Drug Pipeline, Medical and Healthcare Sectors.